Levodopa

This product is a precursor of dopamine synthesized in the body. It has no pharmacological activity itself. It enters the central nervous system through the blood-brain barrier and is converted into dopamine by dopa decarboxylase to exert its effect, improving the regulation of voluntary nerve impulse conduction to the motor cortex and alleviating the symptoms of this disease.

The main ingredient of this product is levodopa

Hepatic coma, Parkinson's disease

1. Treatment of tremor paralysis: Start with 0.1-0.25g each time, 2-4 times a day. Increase the daily dose by 0.25-0.75g every 2-4 days. The general effective dose is 2-5g a day, divided into 4-7 doses, and the effect will be seen after 2-3 weeks of continuous use. During the dose increase process, if nausea occurs, the dose should be stopped and increased again after the symptoms disappear. 2. Treatment of hepatic coma: 0.3-0.4g per day, added to 500ml of 5% glucose solution and dripped intravenously. After fully awake, reduce the dose to 0.2g per day, and stop the drug after 1-2 days. Or add 5g of this product to 100ml of isotonic saline for nasogastric feeding or enema.

There are many adverse reactions, mainly caused by excessive dopamine produced in the periphery. Gastrointestinal reactions such as nausea, vomiting, and loss of appetite occur in about 80% of patients in the early stage of treatment. Psychiatric symptoms such as restlessness, insomnia, and hallucinations may occur after 3 months of medication. In addition, there are postural hypotension, arrhythmia, and involuntary movements. The dosage should be adjusted and the drug should be discontinued if necessary.

It is contraindicated for patients who are allergic to this product, have severe cardiovascular disease, organic encephalopathy, endocrine disorders, mental illness, severe neurasthenia, have used monoamine oxidants within 2 weeks, have angle-closure glaucoma, peptic ulcer, have a history of convulsions, as well as pregnant women, nursing mothers, postpartum women in early pregnancy and children under 12 years old.

Keep away from light and store in sealed container.

Bei Jing Scrianen Pharmaceutical Co., Ltd.

• Founded in:

  2001-12-18

• Address:

  Building 1, No. 3 Yuncheng Street, Beijing Economic and Technological Development Zone, Beijing

• Tax NO.:

  91110302733457016A

• Registered Funds:

  90.354724 million yuan

• Website:

  Log in to view

• Email:

  Log in to view